No headlines found.
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026
Globe Newswire (Fri, 22-May 7:30 AM ET)
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
Globe Newswire (Fri, 15-May 7:30 AM ET)
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer
Globe Newswire (Thu, 14-May 7:30 AM ET)
Globe Newswire (Wed, 13-May 7:30 AM ET)
BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients
Globe Newswire (Tue, 12-May 7:30 AM ET)
Globe Newswire (Thu, 7-May 7:30 AM ET)
BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer
Globe Newswire (Wed, 6-May 7:30 AM ET)
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
Globe Newswire (Mon, 27-Apr 7:30 AM ET)
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models
Globe Newswire (Tue, 21-Apr 7:30 AM ET)
Globe Newswire (Mon, 20-Apr 7:30 AM ET)
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Briacell Therapeutics Corp. - Warrant trades on the NASDAQ stock market under the symbol BCTXZ.
As of May 22, 2026, BCTXZ stock price was flat at $0.08 with 1,000 million shares trading.
BCTXZ has a beta of 4.31, meaning it tends to be more sensitive to market movements. BCTXZ has a correlation of 0.11 to the broad based SPY ETF.
BCTXZ has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
BCTXZ has underperformed the market in the last year with a price return of -93.0% while the SPY ETF gained +29.1%. BCTXZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -52.2% and -11.0%, respectively, while the SPY returned +8.4% and +1.1%, respectively.
BCTXZ support price is $.07 and resistance is $.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTXZ shares will trade within this expected range on the day.